Bleeding Risk for Anti-VEGF and Anticoagulant Co-Administration in Oncology, 2010-2025

A retrospective analysis of 208 patients from Hunan Cancer Hospital between 2010 and 2025, combined with pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) from 2013 to 2024. The dataset, authored by Dehua Liao and last updated in April 2026, assesses bleeding risks associated with concurrent use of anti-VEGF agents and anticoagulants. It includes data on patient demographics, safety outcomes, and duration of co-administration.

Use Cases

• Assessing bleeding risk signals based on co-administration duration data mentioned in the description
• Comparing safety profiles between TKI and Bevacizumab (Bev) patient groups based on the reported cohort sizes
• Analyzing drug-drug interaction signals using the Ω shrinkage measure methodology described
• Evaluating the prevalence of prophylactic versus therapeutic anticoagulant use in the described patient cohorts

Strengths

• Includes data from 208 specific patient records with defined subgroups (83 on TKIs, 125 on Bev)
• Combines hospital data with a large external pharmacovigilance database (FAERS) covering 2013-2024
• Reports specific co-administration durations (e.g., median 4 days for TKI prophylaxis) and bleeding event rates (<6%)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count for the primary tabular data is unknown, which may limit suitability assessment
• Data may reflect geographic bias inherent to its single-hospital source (Hunan Cancer Hospital)

Provenance

Source

Hunan Cancer Hospital and FDA Adverse Event Reporting System (FAERS)

Collection Method

Retrospective analysis combined with pharmacovigilance signal assessment

Time Range

Hospital data: 2010-01-01 to 2025-10-01; FAERS data: Q1 2013 to Q4 2024

Freshness

Last updated 2026-04-07 22:02:24; freshness should be verified

Geography

Primary patient data from Hunan Cancer Hospital, China